According to a June 13, 2022 news release, Vitalunga, a biotech startup based on research led by Professor Einav Gross and Professor Shmuel Ben-Sasson of The Hebrew University's Faculty of Medicine, has developed a novel oral drug [1,8-diaminooctane (VL-004)], that aims to treat and prevent aging-related diseases such as Alzheimer's and Parkinson's. While many successes have been made to extend lifespan in aging adults, disease-free aging has remained a challenge. The novel drug-candidate has the potential to remarkably improve the quality of life of aging adults, according to Yissum, the technology transfer company of the Hebrew University. Vitalunga is currently raising funds in order to begin pre-clinical studies.
Login Or Register To Read Full Story